Weekly Top News – Ovarian Cancer – June 22, 2020

June 22, 2020

Lynparza (olaparib) / Merck (MSD), AstraZeneca; Zejula (niraparib) / GSK, ZAI Lab, J&J, Takeda
Overview of the Updated NCCN Guidelines on Ovarian Cancer (Journal of Clinical Pathways) – Jun 17, 2020 – “The Guidelines added niraparib to maintenance therapy options for those with complete or partial remission if they have BRCA1/2 wild-type or unknown and did not use bevacizumab as primary therapy or for those with germline or somatic BRCA1/2 mutation (category 1 if bevacizumab was not used as a primary therapy, and category 2A if it was). The Guidelines modified a category of evidence for olaparib for patients with a germline or somatic BRCA1/2 mutation who did not receive bevacizumab during primary therapy…”

 

Rubraca (rucaparib) / Clovis
Rubraca: Newly added patents in Orange Book (Orange Book) – Jun 17, 2020 – Expiry on July 23, 2024, August 12, 2027, August 4, 2031 and August 17, 2035

 

Zejula (niraparib) / GSK, ZAI Lab, J&J, Takeda; dostarlimab (TSR-042) / GSK
A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (clinicaltrials.gov) – Jun 18, 2020 – P3; N=1228; Recruiting; Sponsor: Tesaro, Inc.; Trial completion date: Jan 2023 –> Jul 2026; Trial primary completion date: Jul 2021 –> Feb 2023

No Comments

Post a Comment

Comment
Name
Email
Website